Intrauterine PregnancyPULoVRNCT02700789
Pregnancies of Uncertain Location or Viability Research
An observational study of Intrauterine Pregnancy and Ectopic Pregnancy, run by University of Nottingham at 1 site in United Kingdom.
Trial summary
Study to determine the diagnostic accuracy of the double decidual sac sign to predict an intrauterine pregnancy prior to ultrasonographic visualisation of embryonic contents using modern ultrasound technology. Read more about this study
- Who is it for?
- Ages 18 to 45 years, women only
- Conditions the study is for
- Intrauterine Pregnancy, Ectopic Pregnancy
- What is being tested?
- Transvaginal ultrasound scan
- Type of treatment
- Injection or infusion, Surgery or procedure
- How many people
- 79 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- Jan 2015to Dec 2015
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- No healthy volunteers
- Adult
Study population: Participants will be recruited prospectively from Nurture Fertility, Nottingham, United Kingdom between 1st January and 31st October 2015. All women undergoing IVF/ICSI treatment will be invited to participate in the study. no ultrasonographic evidence of an intrauterine fluid collection, or a yolk sac and/or fetal pole was clearly visible within the intrauterine fluid collection. Women were also excluded if no outcome data were available or if, following the reference standard, the final diagnosis was not known (for example resolving or persistent pregnancies of unknown location).
Who may be able to join
- Positive urinary pregnancy test performed 18 days after oocyte retrieval in a fresh treatment cycle or 13-16 days after embryo transfer in a frozen embryo replacement cycle depending on the stage of embryo development at the time of transfer
Who cannot join
- Negative urinary pregnancy test performed 18 days after oocyte retrieval in a fresh treatment cycle or 13-16 days after embryo transfer in a frozen embryo replacement cycle depending on the stage of embryo development at the time of transfer
- No evidence of an intrauterine fluid collection during the index test
- Evidence of a yolk sac and/or fetal pole during the index test
- Final diagnosis not known
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
University of Nottingham
Nottingham, Nottinghamshire, NG7 2RD
About this study
Study to determine the diagnostic accuracy of the double decidual sac sign to predict an intrauterine pregnancy prior to ultrasonographic visualisation of embryonic contents using modern ultrasound technology.
Read the detailed description
This diagnostic accuracy study will be conducted following the standards for reporting of diagnostic accuracy study (STARD) guidelines. Participants will be recruited from Nurture Fertility, Nottingham, United Kingdom at the time of embryo transfer. If the subsequent pregnancy test is positive, participants will be invited to attend for an additional transvaginal ultrasound scan at 33-34 days gestation. This scan will be considered to be the 'index test'.
The index test will be performed by a single investigator with experience in early pregnancy ultrasound following standard operating procedures using a Voluson E8 machine with a high frequency (5-9MHz and 9-12MHz) transvaginal probe. During the early scan the presence or absence of the following structures will be recorded: an intrauterine fluid collection (defined as a uniformly round, hypoechoic structure with an echogenic rim); the double decidual sac sign (DDSS) (defined as two concentric echogenic rings of tissue that surround the intraendometrial fluid collection that impress upon the endometrial stripe); yolk sac (defined as a spherical, hyperechoic ring situated eccentrically within the gestation sac); and fetal pole (defined as a small linear echogenic structure adjacent to the yolk sac, on the side closest to the gestational sac). If more than one intrauterine fluid collection is visualized then each will be considered as a separate entity. The findings from the early scan will be interpreted immediately and recorded separate to the main clinical notes. Participants will be excluded further from the study if at this point no intrauterine fluid collection is detected or if an intrauterine fluid collection containing a yolk sac or fetal pole is identified. Referral pathways to local Early Pregnancy Assessment Units (EPAU) will be in place for any woman in whom this early scan is strongly suggestive of an ectopic pregnancy, for example if there was an empty endometrial cavity and either an inhomogenous adnexal mass or an empty extra-uterine sac or a yolk sac or fetal pole with or without cardiac activity in an extra-uterine sac.
All women will then have a routine viability ultrasound scan at between 6 and 7 weeks gestation as per the fertility unit's standard practice. This viability scan was performed by an appropriately trained doctor or nurse following standard operating procedures and using the same ultrasound equipment as the index test. This viability scan plus any subsequent clinical follow-up required i.e. if the diagnosis was not certain following the viability scan alone, will constituted the reference standard. Clinical follow-up will consist of a repeat transvaginal ultrasound (TVS) 7-10 days after the initial viability scan in cases of pregnancies of uncertain viability (defined as the presence of an intrauterine gestation sac of less than 25mm mean diameter with no obvious yolk sac or fetal pole or an intrauterine gestation sac containing a fetal pole of less than 7mm with no obvious fetal heart pulsations) and in cases of pregnancies of uncertain location (defined as no evidence of an intra- or extra-uterine pregnancy or retained products of conception on transvaginal ultrasound scan in the presence of a positive urinary pregnancy test), referral to a local EPAU for monitoring of serial serum human chorionic gonadotropin (β-hCG) levels and subsequent ultrasonography and possibly surgery where indicated according to departmental protocols until a definitive diagnosis can be made. Interpretation of the reference standard will be performed by an experienced gynaecologist without knowledge of the findings from the index test. Any uncertainty regarding the final diagnosis will be dealt with by seeking the opinion of two other senior gynaecologists and gaining a consensus opinion.
The outcomes of interest are an intrauterine pregnancy (which may be viable or non-viable) or an ectopic pregnancy. A viable intrauterine pregnancy is defined as ultrasonographic identification of an intrauterine gestation sac with a fetal pole of any length with demonstrable fetal heart pulsations. A non-viable intrauterine pregnancy is defined as either an empty intrauterine gestation sac with mean sac diameter greater than 25mm or an intrauterine gestation sac containing a fetal pole with crown rump length greater than 7mm with no demonstrable fetal heart pulsations or in the absence of a viable embryo, no significant increase in the growth of the gestation sac or length of the fetal pole on two ultrasound scans performed more than 7 days apart. Where women undergo surgical or medical management of miscarriage, histological confirmation of the products of conception will be obtained when possible. Ectopic pregnancies will be confirmed either by direct visualisation during surgery with histological confirmation, or, in those managed medically with methotrexate or conservatively, unequivocal identification of an ectopic pregnancy on ultrasound scan. Ultrasonographic appearances indicative of an ectopic pregnancy will include: an empty endometrial cavity with either an inhomogenous adnexal mass or an empty extra-uterine sac or a yolk sac or fetal pole with or without cardiac activity in an extra-uterine sac. Following the reference standard, any pregnancy which does not fall into one of these categories will be excluded from the study. These included resolving or persisting pregnancies of unknown location.
The sensitivity and specificity of the DDSS for predicting an intrauterine pregnancy (IUP) will be estimated following cross tabulation of the index test results against those of the reference standard. The overall diagnostic accuracy, as well as positive and negative likelihood ratios and predictive values, will also be calculated. Results will be expressed as percentages for ease of interpretation and 95% confidence intervals will also be given.
- Conditions
- Intrauterine Pregnancy, Ectopic Pregnancy
- Being tested
- Transvaginal ultrasound scan
- Keywords
- diagnostic accuracy, double decidual sac sign, intrauterine pregnancy
- Medical subject headings
- Pregnancy, Ectopic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Transvaginal ultrasound scanProcedure or surgery
The presence of the following structures will be recorded: an intrauterine fluid collection; the double decidual sac sign; yolk sac; and fetal pole.
| Study group | Role | What they receive |
|---|---|---|
| Pregnant women | Women with a positive urinary pregnancy test following in vitro fertilisation/intracytoplasmic sperm injection (IVF/ICSI) treatment will be invited to attend for an additional transvaginal ultrasound scan at 33-34 days gestation. This will be conducted by a single investigator with experience in early pregnancy ultrasound using a Voluson E8 machine with a high frequency (5-9MHz and 9-12MHz) transvaginal probe and following standard operating procedures. Receives: Procedure: Transvaginal ultrasound scan |
What is being measured
The primary outcome is the main question the study is designed to answer.
Intrauterine Pregnancy
A viable intrauterine pregnancy is defined by ultrasonographic identification of an intrauterine gestation sac with a fetal pole of any length with demonstrable fetal heart pulsations. A non-viable intrauterine pregnancy is defined as either an empty intrauterine gestation sac with mean sac diameter greater than 25mm or an intrauterine gestation sac containing a fetal pole with crown rump length greater than 7mm with no demonstrable fetal heart pulsations or in the absence of a viable embryo, no significant increase in the growth of the gestation sac or length of the fetal pole on two ultrasound scans performed more than 7 days apart. Where women underwent surgical or medical management of miscarriage, histological confirmation of the products of conception will be obtained when possible.
Measured: Repeat transvaginal ultrasound performed 8-16 days after the index test
Secondary outcomes (1)
Ectopic Pregnancy
Ectopic pregnancies will be confirmed either by direct visualisation of an ectopic pregnancy during surgery with histological confirmation, or, in those managed medically with methotrexate or conservatively, unequivocal identification of an ectopic pregnancy on ultrasound scan. Ultrasonographic appearances indicative of an ectopic pregnancy include: an empty endometrial cavity with either an inhomogenous adnexal mass or an empty extra-uterine sac or a yolk sac or fetal pole with or without cardiac activity in an extra-uterine sac
Measured: Repeat transvaginal ultrasound performed 8-16 days after the index test
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Mar 2016 (estimated)
- Study startJan 2015
- Primary completionOct 2015
- Study completionDec 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Intrauterine PregnancyStudies of the same condition, open and under way.
- More trials run by University of NottinghamThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 79 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Nottingham
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02700789
- Sponsor's protocol ID
- 13008
- Acronym
- PULoVR
- Status last verified
- Mar 2016
- First submitted
- 1 Mar 2016
- Last updated
- 7 Mar 2016
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Mar 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pregnancies of Uncertain Location or Viability Research
- ClinicalTrials.gov ID
- NCT02700789
- Acronym / sponsor ID
- PULoVR / 13008
- Conditions
- Intrauterine Pregnancy, Ectopic Pregnancy
- Keywords
- diagnostic accuracy, double decidual sac sign, intrauterine pregnancy
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 79 participants (actual)
- Lead sponsor
- University of NottinghamUniversity, hospital or other
- Study start
- Jan 2015
- Primary completion
- Oct 2015 (actual)
- Study completion
- Dec 2015 (actual)
- First posted
- 7 Mar 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Study to determine the diagnostic accuracy of the double decidual sac sign to predict an intrauterine pregnancy prior to ultrasonographic visualisation of embryonic contents using modern ultrasound technology.
Detailed description
This diagnostic accuracy study will be conducted following the standards for reporting of diagnostic accuracy study (STARD) guidelines. Participants will be recruited from Nurture Fertility, Nottingham, United Kingdom at the time of embryo transfer. If the subsequent pregnancy test is positive, participants will be invited to attend for an additional transvaginal ultrasound scan at 33-34 days gestation. This scan will be considered to be the 'index test'.
The index test will be performed by a single investigator with experience in early pregnancy ultrasound following standard operating procedures using a Voluson E8 machine with a high frequency (5-9MHz and 9-12MHz) transvaginal probe. During the early scan the presence or absence of the following structures will be recorded: an intrauterine fluid collection (defined as a uniformly round, hypoechoic structure with an echogenic rim); the double decidual sac sign (DDSS) (defined as two concentric echogenic rings of tissue that surround the intraendometrial fluid collection that impress upon the endometrial stripe); yolk sac (defined as a spherical, hyperechoic ring situated eccentrically within the gestation sac); and fetal pole (defined as a small linear echogenic structure adjacent to the yolk sac, on the side closest to the gestational sac). If more than one intrauterine fluid collection is visualized then each will be considered as a separate entity. The findings from the early scan will be interpreted immediately and recorded separate to the main clinical notes. Participants will be excluded further from the study if at this point no intrauterine fluid collection is detected or if an intrauterine fluid collection containing a yolk sac or fetal pole is identified. Referral pathways to local Early Pregnancy Assessment Units (EPAU) will be in place for any woman in whom this early scan is strongly suggestive of an ectopic pregnancy, for example if there was an empty endometrial cavity and either an inhomogenous adnexal mass or an empty extra-uterine sac or a yolk sac or fetal pole with or without cardiac activity in an extra-uterine sac.
All women will then have a routine viability ultrasound scan at between 6 and 7 weeks gestation as per the fertility unit's standard practice. This viability scan was performed by an appropriately trained doctor or nurse following standard operating procedures and using the same ultrasound equipment as the index test. This viability scan plus any subsequent clinical follow-up required i.e. if the diagnosis was not certain following the viability scan alone, will constituted the reference standard. Clinical follow-up will consist of a repeat transvaginal ultrasound (TVS) 7-10 days after the initial viability scan in cases of pregnancies of uncertain viability (defined as the presence of an intrauterine gestation sac of less than 25mm mean diameter with no obvious yolk sac or fetal pole or an intrauterine gestation sac containing a fetal pole of less than 7mm with no obvious fetal heart pulsations) and in cases of pregnancies of uncertain location (defined as no evidence of an intra- or extra-uterine pregnancy or retained products of conception on transvaginal ultrasound scan in the presence of a positive urinary pregnancy test), referral to a local EPAU for monitoring of serial serum human chorionic gonadotropin (β-hCG) levels and subsequent ultrasonography and possibly surgery where indicated according to departmental protocols until a definitive diagnosis can be made. Interpretation of the reference standard will be performed by an experienced gynaecologist without knowledge of the findings from the index test. Any uncertainty regarding the final diagnosis will be dealt with by seeking the opinion of two other senior gynaecologists and gaining a consensus opinion.
The outcomes of interest are an intrauterine pregnancy (which may be viable or non-viable) or an ectopic pregnancy. A viable intrauterine pregnancy is defined as ultrasonographic identification of an intrauterine gestation sac with a fetal pole of any length with demonstrable fetal heart pulsations. A non-viable intrauterine pregnancy is defined as either an empty intrauterine gestation sac with mean sac diameter greater than 25mm or an intrauterine gestation sac containing a fetal pole with crown rump length greater than 7mm with no demonstrable fetal heart pulsations or in the absence of a viable embryo, no significant increase in the growth of the gestation sac or length of the fetal pole on two ultrasound scans performed more than 7 days apart. Where women undergo surgical or medical management of miscarriage, histological confirmation of the products of conception will be obtained when possible. Ectopic pregnancies will be confirmed either by direct visualisation during surgery with histological confirmation, or, in those managed medically with methotrexate or conservatively, unequivocal identification of an ectopic pregnancy on ultrasound scan. Ultrasonographic appearances indicative of an ectopic pregnancy will include: an empty endometrial cavity with either an inhomogenous adnexal mass or an empty extra-uterine sac or a yolk sac or fetal pole with or without cardiac activity in an extra-uterine sac. Following the reference standard, any pregnancy which does not fall into one of these categories will be excluded from the study. These included resolving or persisting pregnancies of unknown location.
The sensitivity and specificity of the DDSS for predicting an intrauterine pregnancy (IUP) will be estimated following cross tabulation of the index test results against those of the reference standard. The overall diagnostic accuracy, as well as positive and negative likelihood ratios and predictive values, will also be calculated. Results will be expressed as percentages for ease of interpretation and 95% confidence intervals will also be given.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Pregnant women | – | Procedure: Transvaginal ultrasound scanWomen with a positive urinary pregnancy test following in vitro fertilisation/intracytoplasmic sperm injection (IVF/ICSI) treatment will be invited to attend for an additional transvaginal ultrasound scan at 33-34 days gestation. This will be conducted by a single investigator with experience in early pregnancy ultrasound using a Voluson E8 machine with a high frequency (5-9MHz and 9-12MHz) transvaginal probe and following standard operating procedures. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Participants will be recruited prospectively from Nurture Fertility, Nottingham, United Kingdom between 1st January and 31st October 2015. All women undergoing IVF/ICSI treatment will be invited to participate in the study. no ultrasonographic evidence of an intrauterine fluid collection, or a yolk sac and/or fetal pole was clearly visible within the intrauterine fluid collection. Women were also excluded if no outcome data were available or if, following the reference standard, the final diagnosis was not known (for example resolving or persistent pregnancies of unknown location).
Key inclusion criteria (1 listed)
- Positive urinary pregnancy test performed 18 days after oocyte retrieval in a fresh treatment cycle or 13-16 days after embryo transfer in a frozen embryo replacement cycle depending on the stage of embryo development at the time of transfer
Key exclusion criteria (4 listed)
- Negative urinary pregnancy test performed 18 days after oocyte retrieval in a fresh treatment cycle or 13-16 days after embryo transfer in a frozen embryo replacement cycle depending on the stage of embryo development at the time of transfer
- No evidence of an intrauterine fluid collection during the index test
- Evidence of a yolk sac and/or fetal pole during the index test
- Final diagnosis not known
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Transvaginal ultrasound scanThe presence of the following structures will be recorded: an intrauterine fluid collection; the double decidual sac sign; yolk sac; and fetal pole. | Procedure or surgery | Pregnant women |
Primary outcome
Intrauterine Pregnancy
Time frame: Repeat transvaginal ultrasound performed 8-16 days after the index test
A viable intrauterine pregnancy is defined by ultrasonographic identification of an intrauterine gestation sac with a fetal pole of any length with demonstrable fetal heart pulsations. A non-viable intrauterine pregnancy is defined as either an empty intrauterine gestation sac with mean sac diameter greater than 25mm or an intrauterine gestation sac containing a fetal pole with crown rump length greater than 7mm with no demonstrable fetal heart pulsations or in the absence of a viable embryo, no significant increase in the growth of the gestation sac or length of the fetal pole on two ultrasound scans performed more than 7 days apart. Where women underwent surgical or medical management of miscarriage, histological confirmation of the products of conception will be obtained when possible.
1 secondary outcome
Ectopic Pregnancy
Time frame: Repeat transvaginal ultrasound performed 8-16 days after the index test
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Mar 2016.
- Individual participant dataSharing planned: No
Related trials for Intrauterine Pregnancy
RecruitingObservational study
Growing Little PEAPODS Study
Premature Birth, Premature Infant
Recruiting
Effect of Intrauterine Insemination on Subsequent Pregnancy Outcomes in Couples With Unexplained Pregnancy Loss: A Multicenter, Open-label, Randomized Controlled Trial
Unexplained Pregnancy Loss
RecruitingPhase 2
Statin Intervention for Severe Early-Onset Placental Insufficiency. (STATIN-PRE Trial)
Preeclampsia (PE), Intrauterine Growth Restriction (IUGR)
Active, not recruitingPhase 2
Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer
Atypical Endometrial Hyperplasia, Stage I Uterine Corpus Cancer AJCC v7
RecruitingPhase 2
Neonatal Outcomes on Direct Fetal Intravenous Immunoglobulin During Intrauterine Transfusion for Rhesus Isoimmunization
Hemolytic Disease of the Newborn, Fetal Anemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Intrauterine Pregnancy and Ectopic Pregnancy, run by University of Nottingham at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Mar 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Intrauterine Pregnancy (time frame: Repeat transvaginal ultrasound performed 8-16 days after the index test). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Mar 2016.